Experimental Arrowhead RNAi drug hints at Alzheimer's benefit
Experimental Arrowhead RNAi drug hints at Alzheimer's benefit
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. With Phase 3 data showing a 'potentially best-in-class profile,' Arrowhead plans to submit plozasiran for FDA approval by year-end to rival Ionis's Tryngolza in severe hypertriglyceridemia.
Company Info
Sector:RNA Therapeutics
Headquarters:Pasadena, California, USA
Founded:1989
Website:arrowheadpharma.com/en-us
Upcoming Milestones & Key Dates
Q4 2026
Regulatory
FDA submission for plozasiran
2027
Regulatory
PDUFA decision expected
Clinical Development Pipeline
Plozasiran
Target: APOC3 siRNAPlozasiran
Target: APOC3 siRNAZodasiran
Target: ANGPTL3 siRNARecent News
Arrowhead’s blood-brain barrier tech is ‘arguably better’ than others, analysts say after data drop
Arrowhead Pharmaceuticals' siRNA candidate achieved 'compelling' tau reductions in an early study of healthy volunteers, a magnitude of effect that appears to outperform other blood-brain barrier platforms, according to analysts.
Arrowhead hits 'best-case scenario' with latest results for fat-lowering drug
Arrowhead hits 'best-case scenario' with latest results for fat-lowering drug.
Arrowhead puts pressure on Ionis with positive data for triglyceride lowering drug
With Phase 3 data showing what analysts called a 'potentially best-in-class profile,' Arrowhead Pharmaceuticals plans to submit for FDA approval of plozasiran by the end of the year—hoping to follow to market Ionis Pharmaceuticals' Tryngolza, which got the regulator's nod in severe hypertriglyceridemia last month.
Arrowhead’s gene silencer competitive with Ionis’ in triglyceride disease
Arrowhead’s gene silencer competitive with Ionis’ in triglyceride disease.
Leadership Team
Christopher Anzalone
President and Chief Executive Officer
Javier San Martin
Chief Medical Officer
To be confirmed
Chief Scientific Officer